Jongdae Lee, Professor and Nanshan Scholar, Sino-French Hoffman Institute, School of Basic Medicines, Guangzhou Medical University. He was recruited from University of California, San Diego (UCSD) in 2017, where he worked on the mechanisms of inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). His current research focuses at GMU on developing small molecule drugs for inflammatory diseases and cancer. The two main targets are T cell proliferation and TNF (tumor necrosis factor) signaling since they are the major effectors in chronic inflammatory diseases. For the last 3½ years, his group discovered and characterized 3 small chemicals targeting different pathways.
LNY1 is a potent inhibitor of T cell proliferation and they have identified its chemical structure and mechanism of action. LNY2 is a promoter of T cell proliferation and Treg differentiation, which can be used for adoptive T cell transfer therapies such as CAR T, TILs, and Treg therapy. JND1 is a novel inflammatory stimulus that synergizes with TNF in monocytes. Through these approaches, his group wants to identify novel targets and drugs for inflammation and cancer. His major publications include papers in Nature Cell Biology, Nature Medicine, Proc. Natl Acad Sci U.S.A., J. of Clinical Invest., Science Signaling, and Nature Reviews Immunology.
用户登录
还没有账号?
立即注册